Apyx Medical Corporation (APYX) AI Stock Analysis

Apyx Medical Corporation develops, manufactures, and distributes advanced medical devices for the cosmetic and surgical sectors. Operating through Advanced Energy and Original Equipment Manufacturing (OEM) segments, its flagship Helium Plasma Generator combines radiofrequency energy and helium to cut, coagulate, and ablate soft tissue during open and laparoscopic surgeries. The company provides Renuvion branded products to plastic surgeons and cosmetic physicians for controlled tissue heating, while its J-Plasma line serves hospital surgical suites to improve procedural precision. Additionally, Apyx Medical supplies disposable handpieces, OEM generators, and related accessories.

Revenue increased at a 5-year CAGR of 13.8% from FY2020 to FY2025, reaching $52.8M in FY2025 with 9.9% annual growth. Gross margin stood at 36.0% in FY2025, down from 61.0% in FY2024 and 69.3% in FY2021. Operating margin was -12.2% in FY2025 compared to -39.2% in FY2024, resulting in a net loss of -$11.2M and diluted EPS of -$0.27. For the trailing twelve months ended June 30, 2026, revenue totaled $58.4M with an operating margin of -13.0% and EPS of -$0.20, while the latest quarter saw revenue grow 22.1% year-over-year.

As of June 30, 2026, Apyx Medical held $27.6M in cash and short-term investments against total debt of $39.6M, resulting in net debt of $12.0M. The company maintains a current ratio of 5.68 and a debt-to-equity ratio of 3.72 on shareholders' equity of $10.7M. In FY2025, operating cash flow was -$8.0M and free cash flow was -$9.1M, with capital expenditures of $1.1M. Over the last 5 years, share count expanded by 22.7%.

At its last close of $2.55 on October 16, 2026, Apyx Medical had a market cap of $107.4M and an enterprise value of $136.3M. The stock trades at a price-to-sales ratio of 1.8x, below the 4.1x median of its US-listed Healthcare peers, while its forward P/E of 72.5x is above the peer median of 17.3x. Over the past year, the shares returned -18.0%, trailing the S&P 500 (SPY) return of 16.8%, and the stock's 5-year return of -80.6% lagged the index return of 83.0%.

Wall Street analysts maintain 4 Strong Buy and 2 Buy ratings, with 0 Hold, Sell, or Strong Sell ratings. The mean price target is $6.50, representing a 154.9% premium to the last close of $2.55. For the current fiscal year ending December 31, 2026, consensus estimates project revenue of $59.4M and EPS of -$0.27. For the next fiscal year, 6 analysts forecast revenue of $66.0M and EPS of -$0.25. The company beat EPS estimates in 3 of the last 4 quarters, and its next earnings date is November 5, 2026.

This page is an AI-written research summary of Apyx Medical Corporation (APYX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: APYX income statement, APYX balance sheet, APYX key metrics, APYX analyst forecast, APYX chart. See the APYX stock overview for the latest quote and news.